{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:24:34Z","timestamp":1792801474895,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019638","name":"Key Laboratory of Polysaccharide Bioactivity Evaluation of Traditional Chinese Medicine of Liaoning Province","doi-asserted-by":"publisher","award":["zyyzdxk-2023165"],"award-info":[{"award-number":["zyyzdxk-2023165"]}],"id":[{"id":"10.13039\/501100019638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hypertension is a recognized risk factor for Parkinson\u2019s disease (PD). The renin-angiotensin system (RAS) inhibitors are widely used to treat hypertension. However, the association of RAS inhibitor use with PD has still been an area of controversy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thus, we conducted a meta-analysis to investigate the relationship between RAS inhibitor use and PD. PUBMED\u00a0and EMBASE databases were searched for articles published up to Oct 2023. All studies that examined the relationship between RAS inhibitor use and the incidence of PD were included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seven studies with total 3,495,218 individuals met our inclusion criteria for this meta-analysis. Overall, RAS inhibitor use was associated with a reduction in PD risk (OR\u2009=\u20090.88, 95%CI\u2009=\u20090.79\u20130.98) compared with the controls. When restricted the analysis to individuals with RAS inhibitor use indication, RAS inhibitor exposure was also associated with a decreased risk of PD (OR\u2009=\u20090.76, 95%CI\u2009=\u20090.62\u20130.92). Pooled results of cohort studies also did support a protective role of angiotensin converting enzyme inhibitors (ACEIs) (OR\u2009=\u20090.97, 95%CI\u2009=\u20090.89\u20131.07) users and angiotensin II receptor blockers (ARBs) (OR\u2009=\u20090.8, 95%CI\u2009=\u20090.63\u20131.02) in PD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Overall, RAS inhibitor use as a class is associated with a reduction in PD risk. However, the findings of ACEIs and ARBs may be limited by small sample size. Future well-designed studies considering the classification by inhibitor type, duration, dose, or property of BBB penetration of RAS inhibitors are needed to clarify the contribution of these exposure parameters on the risk of PD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s13760-024-02560-7","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T13:02:05Z","timestamp":1714136525000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Renin-angiotensin system inhibitor use and risk of Parkinson\u2019s disease: a meta-analysis"],"prefix":"10.1007","volume":"125","author":[{"given":"Tian-xiang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8942-4768","authenticated-orcid":false,"given":"Zeng-yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"issue":"10291","key":"2560_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397(10291):2284\u20132303","journal-title":"Lancet"},{"issue":"1","key":"2560_CR2","first-page":"100136","volume":"7","author":"JJ Llibre-Guerra","year":"2022","unstructured":"Llibre-Guerra JJ, Prina M, Sosa AL, Acosta D, Jimenez-Velazquez IZ, Guerra M, Salas A, Llibre-Guerra JC, Valvuerdi A, Peeters G, Ziegemeier E (2022) Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America a community based study. Lancet Reg Health Am 7(1):100136","journal-title":"Lancet Reg Health Am"},{"issue":"10","key":"2560_CR3","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, Bassetti CL, Vos T, Feigin VL (2020) The burden of neurological diseases in Europe: an analysis for the global burden of disease study 2017. Lancet Public Health 5(10):e551\u2013e567","journal-title":"Lancet Public Health"},{"issue":"2","key":"2560_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/med.21996","volume":"44","author":"A Rao","year":"2023","unstructured":"Rao A, Bhat SA, Shibata T, Giani JF, Rader F, Bernstein KE, Khan Z (2023) Diverse biological functions of the renin-angiotensin system. Med Res Rev 44(2):587\u2013605","journal-title":"Med Res Rev"},{"issue":"10","key":"2560_CR5","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/biom12101429","volume":"12","author":"W Bild","year":"2022","unstructured":"Bild W, Vasincu A, Rusu RN, Ababei DC, Stana AB, Stanciu GD, Savu B, Bild V (2022) Impact of the renin-angiotensin system on the pathogeny and pharmacotherapeutics of neurodegenerative diseases. Biomolecules 12(10):1429","journal-title":"Biomolecules"},{"issue":"1","key":"2560_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","volume":"31","author":"J Rodriguez-Pallares","year":"2008","unstructured":"Rodriguez-Pallares J, Rey P, Parga JA, Mu\u00f1oz A, Guerra MJ, Labandeira-Garcia JL (2008) Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 31(1):58\u201373","journal-title":"Neurobiol Dis"},{"issue":"2","key":"2560_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1471-4159.2009.05999.x","volume":"109","author":"B Joglar","year":"2009","unstructured":"Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL (2009) The inflammatory response in the MPTP model of Parkinson\u2019s disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 109(2):656\u2013669","journal-title":"J Neurochem"},{"issue":"16 Pt 2","key":"2560_CR8","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","volume":"70","author":"C Becker","year":"2008","unstructured":"Becker C, Jick SS, Meier CR (2008) Use of antihypertensives and the risk of Parkinson disease. Neurology 70(16 Pt 2):1438\u20131444","journal-title":"Neurology"},{"issue":"5","key":"2560_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/ana.21937","volume":"67","author":"B Ritz","year":"2010","unstructured":"Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 67(5):600\u2013606","journal-title":"Ann Neurol"},{"issue":"10","key":"2560_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.5414\/CP203559","volume":"57","author":"A Warda","year":"2019","unstructured":"Warda A, Reese JP, Tanislav C, Kostev K (2019) The association between antihypertensive therapy and the incidence of Parkinson\u2019s disease in patients followed in general practices in Germany. Int J Clin Pharmacol Ther 57(10):483\u2013488","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"2560_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.amjmed.2022.04.029","volume":"135","author":"HC Lin","year":"2022","unstructured":"Lin HC, Tseng YF, Shen AL, Chao JC, Hsu CY, Lin HL (2022) Association of angiotensin receptor blockers with incident Parkinson disease in patients with hypertension: a retrospective cohort study. Am J Med 135(8):1001\u20131007","journal-title":"Am J Med"},{"issue":"21","key":"2560_CR12","first-page":"e2068","volume":"102","author":"J Romanowska","year":"2023","unstructured":"Romanowska J, Bjornevik K, Cortese M, Tuominen JA, Solheim M, Mofrad AA, Igland J, Scherzer CR, Riise T (2023) Association between use of any of the drugs prescribed in norway and the subsequent risk of Parkinson disease: a drug-wide association study. Neurology 102(21):e2068\u2013e2077","journal-title":"Neurology"},{"issue":"6","key":"2560_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098961","volume":"9","author":"YC Lee","year":"2014","unstructured":"Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS (2014) Antihypertensive agents and risk of Parkinson\u2019s disease: a nationwide cohort study. PLoS ONE 9(6):e98961","journal-title":"PLoS ONE"},{"key":"2560_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.837890","volume":"13","author":"Y Jo","year":"2022","unstructured":"Jo Y, Kim S, Ye BS, Lee E, Yu YM (2022) Protective effect of renin-angiotensin system inhibitors on Parkinson\u2019s disease: a nationwide cohort study. Front Pharmacol 13:837890","journal-title":"Front Pharmacol"},{"key":"2560_CR15","unstructured":"Higgins J, Thomas J, Chandler J, et al (2023) Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane. https:\/\/www.training.cochrane.org\/handbook"},{"issue":"11","key":"2560_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"1","key":"2560_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72(1):39","journal-title":"Arch Public Health"},{"issue":"7109","key":"2560_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta analysis detected by a simple graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"7568","key":"2560_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","volume":"333","author":"J Lau","year":"2006","unstructured":"Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333(7568):597\u2013600","journal-title":"BMJ"},{"issue":"1","key":"2560_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1470320309347789","volume":"11","author":"B Mertens","year":"2010","unstructured":"Mertens B, Vanderheyden P, Michotte Y, Sarre S (2010) The role of the central renin-angiotensin system in Parkinson\u2019s disease. J Renin Angiotensin Aldosterone Syst 11(1):49\u201356","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"10","key":"2560_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","volume":"26","author":"S Perez-Lloret","year":"2017","unstructured":"Perez-Lloret S, Otero-Losada M, Toblli JE, Capani F (2017) Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease. Expert Opin Investig Drugs 26(10):1163\u20131173","journal-title":"Expert Opin Investig Drugs"},{"key":"2560_CR22","first-page":"5780809","volume":"2016","author":"A Mullapudi","year":"2016","unstructured":"Mullapudi A, Gudala K, Boya CS, Bansal D (2016) Risk of Parkinson\u2019s disease in the users of antihypertensive agents: an evidence from the meta-analysis of observational studies. J Neurodegener Dis 2016:5780809","journal-title":"J Neurodegener Dis"},{"issue":"2","key":"2560_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/jnc.15806","volume":"166","author":"TC Santiago","year":"2023","unstructured":"Santiago TC, Parra L, Nani JV, Fidalgo TM, Bradshaw NJ, Hayashi MAF (2023) Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders. J Neurochem 166(2):138\u2013155","journal-title":"J Neurochem"},{"issue":"6","key":"2560_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105402","volume":"89","author":"MA Pou","year":"2022","unstructured":"Pou MA, Orfila F, Pagonabarraga J, Ferrer-Moret S, Corominas H, Diaz-Torne C (2022) Risk of Parkinson\u2019s disease in a gout Mediterranean population: a case-control study. Joint Bone Spine 89(6):105402","journal-title":"Joint Bone Spine"},{"issue":"9","key":"2560_CR25","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1007\/s00415-023-11803-1","volume":"270","author":"A Gialluisi","year":"2023","unstructured":"Gialluisi A, De Bartolo MI, Costanzo S, Belvisi D, Falciglia S, Ricci M, Di Castelnuovo A, Panzera T, Donati MB, Fabbrini G, de Gaetano G, Berardelli A, Iacoviello L (2023) Risk and protective factors in Parkinson\u2019s disease: a simultaneous and prospective study with classical statistical and novel machine learning models. J Neurol 270(9):4487\u20134497","journal-title":"J Neurol"},{"issue":"3","key":"2560_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1161\/HYPERTENSIONAHA.121.17049","volume":"78","author":"JK Ho","year":"2021","unstructured":"Ho JK, Moriarty F, Manly JJ, Larson EB, Evans DA, Rajan KB, Hudak EM, Hassan L, Liu E, Sato N, Hasebe N, Laurin D, Carmichael PH, Nation DA (2021) Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly: a meta-analysis. Hypertension 78(3):629\u2013643","journal-title":"Hypertension"},{"key":"2560_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00778-8","volume":"13","author":"M Ouk","year":"2021","unstructured":"Ouk M, Wu CY, Rabin JS, Jackson A, Edwards JD, Ramirez J, Masellis M, Swartz RH, Herrmann N, Lanct\u00f4t KL, Black SE, Swardfager W (2021) The use of angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers and cognitive decline in Alzheimer\u2019s disease the importance of blood brain barrier penetration and APOE \u03b54 carrier status. Alzheimers Res Ther 13:1\u201315","journal-title":"Alzheimers Res Ther"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02560-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T17:53:14Z","timestamp":1741024394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02560-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2560"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02560-7","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval was required for this review as all data were already published in peer-reviewed journals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}